Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer
The ArtemisR European multi-centre study examined the efficacy and safety of apalutamide plus ADT for patients with mHSPC, further validating the deep and fast PSA response associated with this treatment regimen. These real-world outcomes were additionally observed in a more diverse patient population than that included in the pivotal TITAN study.
Authors
- Martin Lukáč (ORCID: https://orcid.org/0000-0002-8535-6334)
- Julián Oñate-Celdrán (ORCID: https://orcid.org/0000-0003-1621-0187)
- Joana Lencart (ORCID: https://orcid.org/0000-0001-7078-7257)
- I. Latorzeff (ORCID: https://orcid.org/0000-0001-5935-5218)
- Antonio Rosino-Sánchez
- Claudio A. Schioppa (ORCID: https://orcid.org/0000-0002-4148-4676)
- Juan Antonio Encarnación (ORCID: https://orcid.org/0000-0003-1463-9326)
- Suzy Van Sanden
- Eva Hellmis (ORCID: https://orcid.org/0000-0002-7780-8759)
- Mostefa Bennamoun (ORCID: https://orcid.org/0000-0002-0878-5186)
- Krystelle Hanna
- Gero Kramer (ORCID: https://orcid.org/0000-0003-1982-6817)
- W. Leicht
- Louis Marie Dourthe
- Martin Boegemann
- Axel Hegele
Institutions
- Johnson & Johnson (United States) (US)
- Philipps University of Marburg (DE)
- Hospital General Universitario Morales Meseguer (ES)
- Institute Mutualiste Montsouris (FR)
- Comprehensive Cancer Center Vienna (AT)
- University Hospital Münster (DE)
- Krankenhaus Barmherzige Brüder (DE)
- Centre Hospitalier Sainte-Anne (FR)
- Hospital Reina Sofía de Murcia (ES)
- BG Klinikum Duisburg (DE)
- Clinique Pasteur (FR)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Johnson & Johnson (Brazil) (BR)
- Technische Hochschule Mittelhessen (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12885-025-14294-7
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.07